Results 191 to 200 of about 30,955 (215)

Ranibizumab for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine, 2006
Ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--has been evaluated for the treatment of neovascular age-related macular degeneration.In this multicenter, 2-year, double-blind, sham-controlled study, we randomly assigned patients with age-related macular ...
Philip J, Rosenfeld, David M, Brown, Jeffrey S, Heier, David S, Boyer, Peter K, Kaiser, Carol Y, Chung, Robert Y, Kim   +6 more
openaire   +2 more sources

Abicipar pegol for neovascular age-related macular degeneration

Expert Opinion on Biological Therapy, 2020
The development of intravitreal anti-vascular endothelial growth factor (VEGF) therapy has revolutionized management of neovascular age-related macular degeneration (nAMD) and serves as the standard of care for treating this chronic, progressive disease.
Rehan M, Hussain, Christina Y, Weng, Charles C, Wykoff, Raya A, Gandhi, Seenu M, Hariprasad   +4 more
openaire   +2 more sources

NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: ROUNDTABLE

Retina, 2005
Several recent developments may provide an opportunity to improve outcome in individuals who develop neovascular age-related maculopathy (age-related macular degeneration [ARMD]). Concurrent with progress in isolating clinically relevant subtypes of neovascular ARMD, several therapies have been introduced that show promise for halting progression of ...
CHAIRMAN LAWRENCE J. SINGERMAN, ALEXANDER J. BRUCKER, LEE M. JAMPOL, JENNIFER I. LIM, PHILIP ROSENFELD, ANDREW P. SCHACHAT, RICHARD F. SPAIDE   +6 more
openaire   +1 more source

NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Retina, 2005
This review summarizes the data reported in peer-reviewed literature and presents current knowledge on differentiation, natural history, and therapeutic outcomes of neovascular age-related macular degeneration (AMD).The MEDLINE database was searched to review natural history of neovascular AMD and therapeutic effects of available treatments.The search ...
openaire   +2 more sources

Innovative therapies for neovascular age-related macular degeneration

Expert Opinion on Pharmacotherapy, 2019
Introduction: Investigational anti-VEGF treatments for neovascular age-related macular degeneration (nAMD) aim to improve visual outcomes and reduce treatment burden; these include long-acting agents, combination strategies, topical agents, sustained-release, and genetic therapies.
Hasenin, Al-Khersan, Rehan M, Hussain, Thomas A, Ciulla, Pravin U, Dugel   +3 more
openaire   +2 more sources

Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration

Immunotherapy, 2013
Neovascular age-related macular degeneration (AMD) is the leading cause of legal blindness in patients over the age of 50 in the western world. Intravitreally administered anti-VEGF drugs have been developed to halt neovascular growth in AMD. Randomized trials have demonstrated the excellent safety profile and significant benefit of anti-VEGF therapy ...
David, Xu, Peter K, Kaiser
openaire   +2 more sources

Neovascular age-related macular degeneration

2010
David E Lederer, Scott W Cousins, Karl G Csaky   +2 more
openaire   +2 more sources

Macular atrophy development in neovascular age-related macular degeneration

European Journal of Ophthalmology, 2020
Dan Călugăru, Mihai Călugăru
openaire   +2 more sources

Neovascular Age-Related Macular Degeneration

2016
Reinhard Told, Sebastian M. Waldstein, Ursula Schmidt-Erfurth   +2 more
openaire   +1 more source

Neovascular Age-Related Macular Degeneration

2006
ADAM H. ROGERS, ANDRE WITKIN
openaire   +1 more source